June 2017 Issue Table Of Contents

From The Editor

• Biopharma: Judged On Value By Those Who Bring Little

Feature Articles

• How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever
• Our Annual Cancer Immunotherapy Update

Capitol Perspectives

• Drug Costs Moderating, But Growing Copays Fuel Ire

Companies To Watch

• Frequency Therapeutics

CEO Corner

• The Case For A Healthcare Futures Market

Inside The Industry

• Genentech Masters Breakthrough Therapy Designation
• Is The Cuban Biopharma Industry A Forerunner Of Pharma 3.0? Part 2
• Awakening The Biotech Entrepreneurial Spirit
• How NYC Is Building A World-Class Life Science Hub
• Bridging The Gap Between Academia, Small Biotechs, And Industry
• Amorsa’s Self-Funded Path To Big Pharma Partnerships
• Can DalCor Pharma Succeed Where Others Have Failed?
• Prospects For Healthcare Capital Markets In 2017

Leadership Lessons

• The Power of Small Wins — And How to Keep Them Going

Ask The Board

• What Was Your Most Difficult Learning Experience And How Did You Turn It Into A Success Story?
• What Key Trends Are You Seeing In Clinical Development?
• What Advances Are Being Made In Gene Editing, And What Technologies Will Prove Key In Advancing This Space?